A2 Vertaisarvioitu katsausartikkeli tieteellisessä lehdessä

Nanoparticulation of Prodrug into Medicines for Cancer Therapy




TekijätZhang Yuezhou, Cui Huaguang, Zhang Ruiqi, Zhang Hongbo, Huang Wei

KustantajaWILEY

Julkaisuvuosi2021

JournalAdvanced Science

Tietokannassa oleva lehden nimiADVANCED SCIENCE

Lehden akronyymiADV SCI

Artikkelin numero2101454

Vuosikerta8

Numero18

Sivujen määrä34

eISSN2198-3844

DOIhttps://doi.org/10.1002/advs.202101454

Rinnakkaistallenteen osoitehttps://research.utu.fi/converis/portal/detail/Publication/66860641


Tiivistelmä
This article provides a broad spectrum about the nanoprodrug fabrication advances co-driven by prodrug and nanotechnology development to potentiate cancer treatment. The nanoprodrug inherits the features of both prodrug concept and nanomedicine know-how, attempts to solve underexploited challenge in cancer treatment cooperatively. Prodrugs can release bioactive drugs on-demand at specific sites to reduce systemic toxicity, this is done by using the special properties of the tumor microenvironment, such as pH value, glutathione concentration, and specific overexpressed enzymes; or by using exogenous stimulation, such as light, heat, and ultrasound. The nanotechnology, manipulating the matter within nanoscale, has high relevance to certain biological conditions, and has been widely utilized in cancer therapy. Together, the marriage of prodrug strategy which shield the side effects of parent drug and nanotechnology with pinpoint delivery capability has conceived highly camouflaged Trojan horse to maneuver cancerous threats.

Ladattava julkaisu

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.





Last updated on 2024-26-11 at 12:07